A Clinician’s Handbook for Childhood & Adult Immunizations in Georgia

Meningococcal B

Meningococcal Conjugate Vaccine B

(Minimum age: 10 years)

MenB-4c, Bexsero; MenB-FHbp, Trumenba)



Vaccine Description

Inactivated conjugate vaccine, containing Neisseria meningitidis serogroup B.

Dose & Route

0.5 mL given IM


Shared Clinical Decision-Making

Adolescents not at increased risk age 16-23 years (preferred age 16-18 years) based on shared clinical decision-making:

  • Bexsero: 2-dose series at least 1 month apart.
  • Trumenba: 2-dose series at least 6 months apart; if dose 2 is administered earlier than 6 months, administer a 3rd dose at least 4 months after dose 2.

Special Situations

Anatomic or functional asplenia (including sickle cell disease), persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use, and microbiologists routinely exposed to Neisseria meningitidis:

  • Bexsero: 2-dose series at least 1 month apart.
  • Trumenba: 3-dose series at 0, 1-2, 6 months (if dose 2 was administered at least 6 months after dose 1, dose 3 not needed; if dose 3 is administered earlier than 4 months after dose 2, a 4th dose should be administered at least 4 months after dose 3).

MenB-4C and MenB-FHbp are not interchangeable  (use same product  for  all  doses  in  series);  1  dose  MenB booster 1 year after primary series and revaccinate every 2-3 years if risk remains.

Pregnancy: Delay MenB until after pregnancy unless at increased  risk  and  vaccination  benefits  outweigh potential risk.

MenB Booster

For MenB  booster dose recommendations  for groups listed under “Special situations” and in an outbreak setting (e.g., in community or organizational settings and among men who have sex with men) and additional meningococcal vaccination information, see Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020 | MMWR (cdc.gov)


  • Severe allergic reaction after a previous dose of Trumenba.
  • Hypersensitivity, including severe allergic  reaction, to any component of the vaccine,  or after a  previous  dose of BEXSERO.


  • The tip caps for of the pre-filled Bexsero syringes contain natural rubber latex which may cause allergic reactions in latex sensitive individuals.